Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | AML: data to look forward to in 2018 and beyond

Richard Stone • 9 Dec 2017
ASH 2017
Acute Myeloid Leukemia Azacitidine Decitabine Gilteritinib Quizartinib Venetoclax

In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, gives his forecast of the acute myeloid leukemia (AML) data to look forward to in 2018 and beyond. Dr Stone highlights key data due to be release in 2018 for the trials of the second-generation FLT3 inhibitors quizartinib and gilteritinib vs. standard chemotherapy in advanced FLT3-mutated AML. He also anticipates the results of several significant venetoclax trials for AML. Furthermore, he discusses the immunotherapies to look out for, including antibody-drug conjugates, BiTES and DARTs. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

More from Richard Stone

2:02
ISAL session highlights: targeting CD123, CD47 & TP53 in AML
Richard Stone • 21 Mar 2023
2:31
Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications
Richard Stone • 21 Mar 2023
1:14
The potential of uproleselan in patients with AML
Richard Stone • 21 Mar 2023
1:57
Insights into the treatment of patients with FLT3-mutated AML & the role of maintenance therapy
Richard Stone • 21 Mar 2023

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals